Journal Scans
Comparison of Two Neoadjuvant Chemoradiotherapy Regimens for Locally Advanced Rectal Cancer: Results of the Phase III Trial ACCORD 12/0405-Prodige 2
Neoadjuvant Chemoradiotherapy in Locally Advanced Rectal Cancer
J-P Gérard, D Azria, S Gourgou-Bourgade, I Martel-Laffay, C Hennequin, P-L Etienne, V Vendrely, E François, G de La Roche, O Bouché, X Mirabel, B Denis, L Mineur, J-F Berdah, MA Mahé, Y Bécouarn, O Dupuis, G Lledo, C Montoto-Grillot, T Conroy
Yes
20100201
2010 Mar 1
J Clin Oncol
Comparison of Two Neoadjuvant Chemoradiotherapy Regimens for Locally Advanced Rectal Cancer: Results of the Phase III Trial ACCORD 12/0405-Prodige 2
J Clin Oncol. 2010 Mar 1;[Epub Ahead of Print], J-P Gérard, D Azria, S Gourgou-Bourgade, I Martel-Laffay, C Hennequin, P-L Etienne, V Vendrely, E François, G de La Roche, O Bouché, X Mirabel, B Denis, L Mineur, J-F Berdah, MA Mahé, Y Bécouarn, O Dupuis, G Lledo, C Montoto-Grillot, T Conroy
TAKE-HOME MESSAGE
EXPERT COMMENTARY
Abstract
SUMMARY
OncologySTAT Editorial Team
Neoadjuvant chemoradiotherapy improves local control over that of postoperative chemoradiotherapy in patients with T3-4 rectal adenocarcinoma. In this study by Gérard et al, investigators compared the pathologic complete response rates (ypCRs) in patients with resectable T3-4 M0 rectal cancer after treatment with either neoadjuvant radiotherapy (45 Gy) plus capecitabine (Cap 45) or radiotherapy (50 Gy) plus capecitabine plus oxaliplatin (Capox 50). The objective was to evaluate whether the ypCR of...
